ArticleScientific reports2025
Development of COPMAN-Air method for high-sensitivity detection of SARS-CoV-2 in air.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Several studies have successfully detected SARS-CoV-2 in air samples. However, most of these studies focused on validating the air collection method, and there was no report on the development of a virus detection method. In this study, to detect viruses in air samples with greater sensitively than conventional detection methods, we utilized COPMAN, a highly sensitive virus detection method originally used for wastewater samples. We applied COPMAN to air samples, thereby developing COPMAN-Air. Briefly, this method efficiently detects the extremely low levels of viral RNA in air samples via three reaction steps: RT, preamplification, and qPCR, as it is performed with COPMAN. We evaluated COPMAN-Air using samples from a fever clinic for COVID-19 patients. COPMAN-Air demonstrated a higher detection rate of viral RNA compared with conventional methods, detecting the virus in 22 out of 23 samples (95.7%) vs. 14 out of 23 samples (60.9%). Additionally, a positive correlation (r = 0.70) was detected between the amount of viral RNA detected by COPMAN-Air and the number of confirmed COVID-19 cases, suggesting that COPMAN-Air could estimate the number of SARS-CoV-2-positive individuals in a given space based on the quantitative values of SARS-CoV-2 RNA in air samples. Surveillance systems for airborne pathogens using COPMAN-Air are expected to be valuable for estimating the number of infected individuals and for guiding the implementation of public health measures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.